Financial Performance - The company's revenue for Q1 2022 reached ¥827,689,742.45, representing a 132.24% increase compared to ¥356,396,881.76 in the same period last year[6] - Net profit attributable to shareholders was ¥177,239,159.96, up 232.41% from ¥53,319,684.80 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥173,781,718.39, reflecting a 263.68% increase from ¥47,783,712.76 in the previous year[6] - Basic earnings per share rose to ¥0.4425, a 192.47% increase from ¥0.1513 in the same quarter last year[6] - The operating profit for Q1 2022 was CNY 279,726,066.78, a substantial increase from CNY 77,667,523.86 in Q1 2021[22] Assets and Liabilities - The company's total assets increased by 17.44% to ¥2,472,703,335.31 from ¥2,105,485,351.52 at the end of the previous year[6] - The total liabilities rose to CNY 600,947,135.34, up from CNY 465,671,496.04, marking an increase of 28.9%[20] - The company's total non-current assets amounted to CNY 360,229,253.40, an increase from CNY 338,412,008.50 at the beginning of the year[20] - The company’s fixed assets increased to ¥178,774,710.30 from ¥161,409,330.09, showing a growth of about 10.8%[18] Cash Flow - The net cash flow from operating activities was negative at -¥152,146,040.01, worsening by 1,036.60% compared to -¥13,386,101.96 in the previous year[6] - The cash inflow from operating activities was CNY 400,535,151.96, an increase of 37.5% compared to CNY 291,363,958.94 in the previous period[24] - The cash inflow from investment activities was CNY 371,725,372.46, significantly up from CNY 50,936,315.54 in the previous period[26] - The total cash and cash equivalents at the end of the period were CNY 243,996,627.33, an increase from CNY 176,990,248.95 in the previous period[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 26,865[14] - The largest shareholder, Shanghai Lanwei Investment Co., Ltd., holds 37.34% of the shares, totaling 149,554,017 shares[14] - The company released 2,645,893 restricted shares for trading on March 14, 2022, accounting for 0.6606% of the total share capital[15] - The total number of restricted shares held by major shareholders remains unchanged, with the next release date set for September 13, 2022, for some shareholders[16] Research and Development - Research and development expenses surged by 106.19% to ¥12,493,191.61, indicating a strong commitment to R&D projects[11] - Research and development expenses for Q1 2022 were CNY 12,493,191.61, which is a 106.4% increase from CNY 6,059,086.25 in Q1 2021[22] Business Growth - Accounts receivable increased by 57.31% to ¥1,249,539,766.46, driven by rapid business growth[10] - The company reported a significant increase in sales revenue, leading to a 38.54% rise in cash received from sales of goods and services to ¥396,221,427.14[11] - The company reported a significant increase in accounts payable, which rose to CNY 349,968,289.17 from CNY 253,030,352.86, reflecting a growth of 38.3%[20] - The company signed a significant contract with Hissen Meikang Medical Electronics (Shanghai) Co., Ltd. for a platform business in in vitro diagnostic products, effective from April 1, 2022, to March 31, 2023[15] Other Information - The company has not reported any new product launches or technological advancements in this quarter[15] - The cash and cash equivalents decreased to ¥244,484,061.57 from ¥351,962,422.05 at the beginning of the year, indicating a decline of approximately 30.5%[18] - The company’s cash outflow for purchasing fixed assets was CNY 36,016,213.18, up from CNY 18,915,017.18 in the previous period[26] - The company’s cash outflow for employee payments was CNY 115,869,709.92, increasing from CNY 67,721,931.32 in the previous period[24]

Financial Performance - The company's operating revenue for 2021 was ¥1,778,332,831.11, representing a 43.62% increase compared to ¥1,238,190,078.78 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥203,840,333.57, an increase of 84.68% from ¥110,376,326.73 in 2020[20]. - The net profit after deducting non-recurring gains and losses was ¥181,968,351.79, up 72.39% from ¥105,554,432.51 in 2020[20]. - The company's total assets at the end of 2021 were ¥2,105,485,351.52, a 43.08% increase from ¥1,471,513,584.46 at the end of 2020[20]. - The basic earnings per share for 2021 was ¥0.5783, an increase of 84.64% compared to ¥0.3132 in 2020[20]. - The weighted average return on equity for 2021 was 15.00%, up from 9.21% in 2020, reflecting a 5.79% increase[20]. - The net cash flow from operating activities for 2021 was ¥223,510,224.74, a 33.14% increase from ¥167,874,989.16 in 2020[20]. - The company reported a quarterly revenue of ¥503,747,694.06 in Q4 2021, maintaining strong performance in the last quarter[22]. - The company received government subsidies amounting to ¥14,132,997.85 in 2021, compared to ¥12,840,597.43 in 2020[25]. - Medical diagnostic service revenue reached ¥947,219,293.77, a year-on-year increase of 102.02%[77]. - In vitro diagnostic product sales totaled ¥819,201,241.82, reflecting a year-on-year growth of 7.44%[80]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares to all shareholders, based on a total of 400,517,000 shares[5]. - The company held a temporary shareholders' meeting on December 17, 2021, with a participation rate of 70.93%[172]. - The company reported a participation rate of 83.65% in the annual shareholders' meeting held on April 20, 2021[172]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 6.6831 million yuan[184]. - The highest remuneration was received by the chairman and general manager, totaling 2.2941 million yuan[185]. Risk Management and Compliance - The report emphasizes the importance of risk awareness regarding future plans and development strategies, indicating potential risks and countermeasures[5]. - The report outlines the company's operational risks and the strategies in place to mitigate these risks, which are crucial for future growth[5]. - The company faces risks related to policy changes and technological innovation, which may impact its operational model and market rules[142][143]. - The company faces quality control risks, as any service quality issues could adversely affect patient treatment and lead to legal disputes, impacting market reputation and operational performance[148]. - The company is committed to strengthening accounts receivable management through enhanced tracking mechanisms and credit systems to control bad debt occurrences[150]. Operational Strategy and Market Position - The company is focused on expanding its market presence and enhancing its service offerings[5]. - The company has established partnerships with leading diagnostic firms to enhance its technological capabilities[13]. - The company focuses on providing comprehensive medical diagnostic services and IVD product sales to various healthcare institutions[30]. - The integration of third-party medical diagnostic services with in vitro diagnostic product sales enhances the company's influence and competitiveness in the region[52]. - The company has developed a comprehensive regional center service system that integrates testing, pathology, public health, and precision medicine, enhancing diagnostic capabilities for regional medical institutions[57]. Research and Development - R&D investment amounted to ¥39,441,529.24, representing an 80.91% increase compared to the previous year[82]. - The company aims to increase investment in technology research and development, with a focus on building an international-level research and experimental environment over the next three years[130]. - The introduction of new technologies such as single-cell sequencing and spatial transcriptomics to enhance research and clinical applications[78]. - The company has developed a cloud-based laboratory information management system to facilitate real-time data sharing among medical institutions[67]. - The company has integrated advanced technologies such as PCR and mass spectrometry into its testing platforms, enhancing efficiency and reducing costs[65]. Corporate Governance - The company has established a robust internal management structure, ensuring independent operational authority[170]. - The company has maintained a stable governance structure with no reported changes in the board composition during the reporting period[175]. - The company has independent directors and supervisors who do not receive remuneration from related parties[185]. - The company has a clear policy for remuneration approval that involves multiple levels of review and approval[184]. - The company has established a dedicated investor relations management system, with a designated secretary responsible for coordinating investor communications[163]. Social Responsibility and Community Engagement - The company actively engaged in social responsibility initiatives, including donations to underprivileged areas and support for children with autism[86][87]. - The company respects the rights of stakeholders and emphasizes social responsibility, aiming for a balance of interests among shareholders, employees, and society[164]. Employee Management and Development - The total number of employees at the end of the reporting period was 1,522, with 277 in the parent company and 348 in major subsidiaries[196]. - The professional composition included 715 technical personnel, 259 sales personnel, and 485 administrative personnel[196]. - The company's compensation policy is linked to market conditions, job evaluations, and employee performance, comprising basic salary, performance pay, efficiency pay, allowances, and bonuses[198]. - The company has implemented an annual training plan based on strategic planning and employee capability assessments, focusing on management skills and compliance with quality standards[199]. - Training for middle and senior management aims to enhance management capabilities and align with the company's core culture and values[199].

Financial Performance - The company's revenue for Q3 2021 reached ¥503,293,812.78, representing a year-over-year increase of 38.57%[8] - Net profit attributable to shareholders was ¥79,181,669.88, up 72.20% compared to the same period last year[8] - The net profit after deducting non-recurring gains and losses was ¥77,424,610.62, reflecting a 66.99% increase year-over-year[8] - Total operating revenue for Q3 2021 reached ¥1,274,585,137.05, a significant increase of 47.6% compared to ¥863,722,830.58 in Q3 2020[23] - Net profit for Q3 2021 was ¥225,095,776.79, representing a 104.5% increase from ¥109,948,307.06 in Q3 2020[24] - Earnings per share for Q3 2021 were ¥0.5032, compared to ¥0.2634 in Q3 2020, reflecting a growth of 91.1%[25] - The total comprehensive income for Q3 2021 was ¥225,095,776.79, compared to ¥109,948,307.06 in Q3 2020, indicating strong growth in overall profitability[25] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,983,807,135.22, a 34.81% increase from the end of the previous year[8] - Total assets as of September 30, 2021, amounted to ¥1,983,807,135.22, an increase of 34.7% from ¥1,471,513,584.46 at the end of 2020[21] - Total liabilities increased to ¥367,427,290.45, up 64.0% from ¥224,131,297.98 at the end of 2020[21] - The company's equity attributable to shareholders reached ¥1,538,448,316.65, a rise of 26.0% from ¥1,222,264,042.61 at the end of 2020[21] - Total liabilities rose to ¥292,624,792.11 from ¥224,131,297.98, representing an increase of approximately 30.6%[32] Cash Flow - Cash flow from operating activities showed a net outflow of ¥52,558,365.95, a significant decline of 408.71% compared to the previous year[12] - Cash inflow from operating activities increased to ¥1,008,192,482.15, up from ¥789,891,349.66, representing a growth of approximately 27.8%[27] - Cash outflow from operating activities rose to ¥1,060,750,848.10, compared to ¥772,866,278.35, indicating an increase of about 37.2%[27] - Cash inflow from investment activities decreased to ¥193,242,445.52 from ¥471,333,090.71, reflecting a drop of approximately 59.0%[28] - Net cash flow from investment activities was -¥117,042,737.52, a significant decline from a positive ¥17,479,692.19 in the prior period[28] - Cash inflow from financing activities increased to ¥167,627,777.90, up from ¥1,575,000.00, marking a substantial rise of over 10,500%[28] - Net cash flow from financing activities was positive at ¥165,579,634.56, compared to a negative -¥93,474,970.14 in the previous period[28] - The ending cash and cash equivalents balance was ¥348,177,024.79, a decrease from ¥197,010,946.59, indicating a reduction of approximately 43.5%[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,634[15] - Shanghai Lanwei Investment Co., Ltd. holds 37.34% of shares, totaling 149,554,017 shares[15] - The top ten shareholders collectively hold significant stakes, with the largest shareholder owning over 37%[15] - The total number of unrestricted shares held by the top ten unrestricted shareholders is 1,000,000[15] - The company has a total of 352,455,000 restricted shares, with no shares released during the reporting period[17] - The company plans to release 4,806,200 shares from the initial public offering on September 13, 2022[17] Research and Development - Research and development expenses increased by 45.06% to ¥22,993,309.05, indicating a strong commitment to innovation[12] - Research and development expenses for Q3 2021 were ¥22,993,309.05, an increase of 45.0% compared to ¥15,851,160.07 in Q3 2020[24] - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[15] Other Financial Information - The weighted average return on equity was 5.82%, an increase of 51.17% compared to the same period last year[8] - The company reported a financial expense of ¥787,507.68, compared to a financial income of ¥342,952.76 in the previous year[24] - The company adopted the new leasing standards starting January 1, 2021, impacting financial statement disclosures[34] - The third quarter report for 2021 has not been audited[35]